Potassium chloride transporter activator - OMass Therapeutics
Alternative Names: KCC2 activator; KCC2/SLC12A5 activator; Potassium chloride transporter, solute carrier family 12 member 5 - OMass Therapeutics; SLC12A5 activatorLatest Information Update: 28 Dec 2025
At a glance
- Originator OMass Therapeutics
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action Potassium channel agonists; Solute carrier protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for research development in Epilepsy in United Kingdom
- 04 Nov 2021 Early research in Epilepsy in United Kingdom (unspecified route) prior to November 2021
- 03 Jan 2017 Oxford University Innovation has worldwide patent protection for method to detect complex of membrane protein bound to a therapeutic agent by mass spectrometry, in USA and Europe